Cover Image
市場調查報告書

Cimzia (certolizumab pegol) (類風濕性關節炎治療藥) - 2023年前的預測與市場分析

Cimzia (certolizumab pegol) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 259977
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
Cimzia (certolizumab pegol) (類風濕性關節炎治療藥) - 2023年前的預測與市場分析 Cimzia (certolizumab pegol) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 61 Pages
簡介

本報告提供類風濕性關節炎治療藥物──Cimzia之相關調查,提供您類風濕性關節炎概要和治療藥的競爭趨勢,產品資訊,銷售額預測等資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 疾病的管理

  • 疾病和治療概要
    • 診斷
    • 治療指南
    • 類風濕性關節炎治療用主要處方藥
    • 臨床診療

第5章 競爭評估

  • 概要

第6章 Cimzia (certolizumab pegol)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC496DFR

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

UCB's Cimzia is a pegylated Fab fragment of a humanized anti-TNF IgG molecule, and is indicated for the treatment of adult patients with moderate to severe RA. It is self-administered once every two or four weeks by SC injection. Cimzia dampens the inflammatory process, reducing the rate of progressive joint damage, thus improving physical function. Cimzia is a small antibody, with a mass of about 40kDa (kilodaltons); therefore, it lacks the ability to cross-link, and it also lacks an Fc region. Clinical evidence suggests that Cimzia has an efficacy and safety profile similar to other TNF inhibitors, which may be attributable to its ability to penetrate inflamed joints more efficiently due to its small size. Cimzia is also indicated for Crohn's disease, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.

Scope

  • Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Cimzia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Cimzia for the top nine countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Cimzia performance.
  • Obtain sales forecast for Cimzia from 2013-2023 in top nine countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia and China).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Leading Prescribed Drugs for the Treatment of RA
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Cimzia (certolizumab pegol)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed RA Patients
    • 7.4.2. Percentage of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic and Biosimilar Erosion
  • 7.5. Primary Research - KOLs Interviewed for This Report
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Reviewer
    • 7.7.3. Therapy Area Director
    • 7.7.4. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Symptoms of RA
  • Table 2: 1987 ACR Diagnostic Criteria for RA
  • Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA
  • Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM
  • Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity
  • Table 6: EULAR 2013 Criteria for RA Remission
  • Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014
  • Table 8: Leading Branded Treatments for RA 2014
  • Table 9: Product Profile - Cimzia
  • Table 10: Cimzia SWOT Analysis, 2014
  • Table 11: Global Sales Forecasts ($m) for Cimzia, 2013-2023
  • Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Normal Synovial Joint and Synovial Joint with RA
  • Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
  • Figure 3: Disease Management Flowchart for Early RA - ACR 2012
  • Figure 4: Disease Management Flowchart for Established RA - ACR 2012
  • Figure 5: Flowchart for the Management of RA - EULAR 2013
Back to Top